Eli Lilly Gains FDA Approval for Oral GLP-1 Pill Delivering 12–15% Weight Loss
FDA approved Foundayo, Eli Lilly’s once-daily oral GLP-1 obesity pill, after trials showed 12–15% body weight loss. Starting April 6, self-pay pricing ranges from $149 to $349 monthly (as low as $25 with insurance), while Indian generics at $10–$50 threaten long-term pricing power.
1. FDA Approval and Efficacy
The FDA approved Foundayo (orforglipron), making it one of the first oral GLP-1 drugs specifically for obesity. Phase 3 trials demonstrated 12–15% average body weight loss, positioning the small-molecule pill just below the most powerful injectables.
2. Launch Plan and Pricing
Foundayo launches April 6 via LillyDirect before rolling out to pharmacies and telehealth platforms. Self-pay pricing starts at $149 monthly for the lowest dose, rising to $349 for higher strengths, with insured patients paying as little as $25.
3. Competitive and Generic Pressure
Oral GLP-1 drugs are expected to capture about 20% of the market by 2030, but small-molecule formulations face easier replication. Over 40 Indian manufacturers have introduced more than 50 generics at $10–$50 monthly, posing a significant threat to pricing power.